NEW SYSTEM THAT DEFINES HUNTINGTON’S DISEASE WILL ‘REVOLUTIONISE’ DRUG TRIALS
A novel staging framework that assesses the progression of Huntington’s disease (HD), similar to the way cancer is staged 0 to 4, has been developed by UCL scientists as part of an international consortium; paving the way for clinical trials of drugs in the earliest stages of HD.
